



OPEN

Genomic analysis of early-stage lung cancer reveals a role for *TP53* mutations in distant metastasis

Debra Van Egeren^{1,2,3,15,36}, Khushi Kohli^{1,36}, Jeremy L. Warner^{4,5}, Philippe L. Bedard⁶, Gregory Riely⁷, Eva Lepisto^{8,16}, Deborah Schrag⁷, Michele LeNoue-Newton⁹, Paul Catalano¹, Kenneth L. Kehl⁸, Franziska Michor^{1,10,11,12,13,14}✉ & for the AACR Project GENIE Consortium represented by Shawn Sweeney*

Patients with non-small cell lung cancer (NSCLC) who have distant metastases have a poor prognosis. To determine which genomic factors of the primary tumor are associated with metastasis, we analyzed data from 759 patients originally diagnosed with stage I–III NSCLC as part of the AACR Project GENIE Biopharma Collaborative consortium. We found that *TP53* mutations were significantly associated with the development of new distant metastases. *TP53* mutations were also more prevalent in patients with a history of smoking, suggesting that these patients may be at increased risk for distant metastasis. Our results suggest that additional investigation of the optimal management of patients with early-stage NSCLC harboring *TP53* mutations at diagnosis is warranted in light of their higher likelihood of developing new distant metastases.

Distant metastasis in non-small-cell lung cancer (NSCLC) is associated with a poor survival of only 6% at 5 years after primary diagnosis¹. About 50% of patients present with distant metastases at the time of diagnosis (i.e., Stage IV)², and ~34% of patients diagnosed with stage I–II disease develop metastases five years after diagnosis³. While some studies suggest that specific mutations (e.g., in *EGFR*) increase the risk of distant metastasis⁴, other results indicate that these mutations do not significantly affect metastasis development⁵. To further investigate this question, we performed a retrospective analysis of 759 patients with stage I–III NSCLC who underwent targeted sequencing of their primary tumors as part of the AACR Project GENIE BPC NSCLC v2.1-consortium dataset⁶ to determine if specific mutations and copy number alterations common in NSCLC are associated with metastasis to distant sites.

We used multivariate Cox proportional hazards models to quantify the association between common genomic alterations in the primary tumor and the rate of developing distant metastases in NSCLC patients diagnosed with local or locally advanced disease (stages I–IIIB; Fig. 1A, Supplementary Table 1, Methods). We investigated associations between nonsynonymous mutations in 5 of the most commonly mutated genes in NSCLC (*TP53*, *KRAS*, *EGFR*, *BRAF*, *PIK3CA*) and copy number changes in 5 of the most commonly amplified genes (*EGFR*, *PIK3CA*, *MET*, *KRAS*, *FGFR1*) and the likelihood of developing metastases. We found that *TP53* mutations were associated with a significantly increased rate of developing metastases to any distant site after diagnosis (Fig. 1B,C; HR = 1.43, HR 95% CI 1.09–2.90, $p = 0.033$, Wald's Test with Benjamini-Hochberg (BH) adjustment for multiple hypothesis testing).

¹Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. ²Department of Systems Biology, Harvard Medical School, Boston, MA, USA. ³Stem Cell Program, Boston Children's Hospital, Boston, MA, USA. ⁴Department of Medicine, Vanderbilt University, Nashville, TN, USA. ⁵Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA. ⁶Department of Medicine, University of Toronto, Toronto, ON, Canada. ⁷Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ⁹Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁰Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. ¹¹Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹²Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ¹³The Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. ¹⁴The Ludwig Center at Harvard, Boston, MA, USA. ¹⁵Department of Medicine, Weill Cornell Medicine, New York, NY, USA. ¹⁶Present address: Multiple Myeloma Research Foundation, Norwalk, CT, USA. ³⁶These authors contributed equally: Debra Van Egeren and Khushi Kohli. *A list of authors and their affiliations appears at the end of the paper. ✉email: michor@jimmy.harvard.edu




Figure 1. *TP53* mutations are significantly associated with the development of distant metastases after diagnosis in early-stage NSCLC. **(A)** Overview of study design. **(B)** Cox regression hazard ratios of each mutation and copy number alteration analyzed, with significant results ($\alpha = 0.05$) in red. Error bars are Bonferroni-adjusted 95% confidence intervals. **(C)** Kaplan–Meier curves showing time to first distant metastasis among patients with early-stage disease, stratified by *TP53* mutation status in the primary tumor. Error bars are 95% confidence intervals. **(D)** Cox regression hazard ratios for *TP53* mutation for metastasis to individual sites, with significant results ($\alpha = 0.05$) in red. Error bars are Bonferroni-adjusted 95% confidence intervals. **(E)** Fraction of patients diagnosed at each stage, stratified by *TP53* mutation status. Error bars denote 95% confidence intervals. **(F)** Kaplan–Meier curves showing overall survival probability stratified by *TP53* mutation status, for patients diagnosed with stage I–III disease. Error bars are 95% confidence intervals. Colors for all panels denote primary tumor *TP53* mutation status (dark blue: mutant, teal: wild-type). In all Cox regressions, we incorporated age, sex, race, ethnicity, smoking history, stage at diagnosis, and 10 total mutations/copy number alterations as covariates (Methods).

We also investigated associations between these mutations and CNAs and the development of metastases to specific distant sites individually (Fig. 1D) and found that *TP53* mutations were associated with a significantly increased rate of metastasis to the liver (HR = 2.51, HR 95% CI 1.07–5.93, BH-adjusted $p = 0.026$, Wald's Test). However, no significant associations between any genomic alterations and the metastasis rate to brain or bone specifically were observed (Supplementary Fig. 1). We found that *TP53* mutation status was not significantly associated with NSCLC stage at diagnosis ($p = 0.21$, χ^2 test) (Fig. 1E), but was significantly associated with reduced overall survival in patients diagnosed with stage I–III NSCLC (Fig. 1F and Supplementary Fig. 2; HR = 1.97, HR 95% CI 1.45–2.66, $p < 1e-04$, Wald's test).

Given the prognostic significance of *TP53* mutations in NSCLC, we analyzed the location and identity of *TP53* mutations found in primary tumors using an expanded cohort of 1,034 patients with stage I–IV disease (Methods). *TP53* mutations in cancer have previously been shown to occur mostly in the DNA binding domain^{7,8}, suggesting that these mutations are likely to impair protein function. Of the 331 patients in our cohort with nonsynonymous point mutations or indels in *TP53*, 285 had mutations localized within the p53 DNA binding domain, most of which are single nucleotide substitutions (Fig. 2A). However, the splice site or frameshift insertions or deletions ($n = 52$ mutations) were more evenly spread throughout the coding sequence, likely because these mutations have a greater impact on protein function regardless of location.

We also found that *TP53* mutations were enriched in patients with a smoking history ($p = 0.0023$, χ^2 test; odds ratio 1.66; Fig. 2B). Single nucleotide substitutions in *TP53* in smokers had a significantly different pattern of base substitutions than nonsmokers, with a higher rate of C > A substitutions found in smokers (Fig. 2C). This pattern is similar to the mutational signature associated with tobacco smoking in cancers of the lung and larynx⁹. The different mutational processes active in smokers and never-smokers were shown to result in differences in the frequency of *TP53* mutations¹⁰. We found that the most common point mutation in smokers (R158L) is less common in never-smokers (14/256 point mutations in smokers, vs. 0/57 in never smokers), although this difference was not significant ($p = 0.15$, χ^2 test; Fig. 2D). This mutation has previously been shown to be more prevalent in




Figure 2. *TP53* SNVs are found in the DNA binding domain and are associated with smoking. **(A)** Location of nonsynonymous SNVs and/or frameshift indels in the *TP53* gene in primary tumor samples from stage I-IV NSCLC patients. The location of the p53 DNA binding domain is shown as an orange shaded region. **(B)** Fraction of patients with a *TP53* mutation, stratified by smoking history. **(C)** Frequency of specific nonsynonymous single nucleotide substitutions in *TP53* in patients without a history of smoking (light grey) and patients with a history of smoking (dark grey). In **(B)** and **(C)**, error bars denote 95% Bayesian credible intervals. **(D)** Location of nonsynonymous SNVs and frameshift indels in smokers and nonsmokers, with amino acid position 158 highlighted in red.

lung cancers¹⁰ and is associated with changes in cell motility and drug sensitivity *in vitro*¹¹. In summary, patients with NSCLC with a history of smoking had more frequent mutations in *TP53*, likely due to smoking-related mutational processes. Our Cox modeling results (Fig. 1) suggest that this increased *TP53* mutation burden is associated with increased risk of developing distant metastases after diagnosis.

Our work has several limitations. First, as our study retrospectively examined the effect of genomic alterations on patient outcome, differences in treatment or other factors associated with specific mutations (e.g., administration of targeted therapies to patients with *EGFR* mutations) made it difficult to isolate the effect of certain genomic changes. Additionally, our study is vulnerable to selection bias and to informative cohort entry^{12,13}, since it only included patients who underwent primary tumor genomic sequencing, which is more likely to be performed in patients who later developed recurrent or progressive disease.

In summary, we found that *TP53* mutations are associated with distant recurrence in patients with NSCLC who were diagnosed with stage I-III disease. Our results suggest that *TP53* mutation status should be regularly tracked in all prospective adjuvant trials in early-stage NSCLC, so that the effect of this frequent mutation can be better understood. While previous clinical trials suggest that adjuvant therapy with cisplatin-based regimens does not improve survival in patients with early-stage *TP53*-mutant NSCLC relative to patients with *TP53*-wild type disease^{14,15}, other therapies (e.g., immunotherapy) could provide a survival advantage to this population¹⁶. Given the potential for distant recurrence in this population, additional investigation of the optimal management strategy for patients with *TP53*-mutant NSCLC is warranted.

Methods

Participant eligibility and selection. Clinical and genomic data for 1,862 patients with NSCLC were collected as part of AACR Project GENIE (BPC NSCLC version 2.1) (Fig. 1A; Supplementary Table 1). Permission to access the data was granted by the AACR Project GENIE Biopharmaceutical Consortium publications committee. All patient data was anonymized before retrieval. The Dana-Farber/Harvard Cancer Center Institutional Review Board determined that this study did not constitute human subjects research, given its use of a previously collected, deidentified dataset. All research was performed in accordance with the Declaration of Helsinki. Data from patients with a NSCLC diagnosis of any stage and who received targeted genomic sequencing of a primary tumor and/or a metastasis biopsy at Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, or Vanderbilt-Ingram Cancer Center between 1/1/2014 and 12/31/2017, or at Princess Margaret Cancer Center (Toronto, CA) between 1/1/2014 and 12/31/2015 were collected in the BPC dataset. Additionally, the BPC study only included patients that were between 18 and 89 years of age at the time of sequencing and who were followed for at least two years after sequencing (or until death). For patients who had tumor sequencing performed on a research basis, informed consent for use of genomic and clinical data were obtained; for those who had sequencing performed on a standard of care clinical basis, data were collected under a waiver of informed consent at respective institutions. For this study, only patients with sequencing of at least one primary tumor sample were included, and only primary tumor sequencing data was used for all analyses. American Joint Committee on Cancer (AJCC) TNM tumor stage was determined in accordance with current guidelines at the time of diagnosis (AJCC guidelines version 6 or 7). Only patients with stage I-III disease at diagnosis were used for Cox proportional hazards modeling to study the association between primary tumor genomics, distant metastasis, and survival, while all patients (including patients with stage IV disease) were used to study the pattern of mutations that occur in the *TP53* gene in NSCLC.

Clinical and genomic data collection. Targeted sequencing of primary tumor samples was performed using institution-specific clinical next-generation sequencing panels. The tumor sequencing panels used and variant calling pipeline for the AACR Project GENIE are as previously described⁶.

Imaging records and medical oncologists' notes were curated according to the PRISMM framework¹⁷ to determine when and where metastases appeared in each patient. Each radiologist report was reviewed to determine whether cancer was present and in which anatomical sites the tumor was found. These notes were used to determine the length of time from diagnosis of the primary tumor to the time at which disease was first observed at each distant site. The time to first distant metastasis was defined as the earliest time after diagnosis at which the patient had an extra-thoracic lymph node or organ metastasis, or a metastasis to the mediastinum, heart, or pleura. No patients in the analysis of association between primary tumor genomics and distant metastases had distant metastases at the time of diagnosis.

Statistical analysis of time to new distant metastases. We used multivariable Cox proportional hazards models to test whether a priori defined static covariates were significantly associated with the development of new distant metastases after diagnosis in patients with stage I-III NSCLC. Six demographic and clinical covariates were included in each model: age at diagnosis, smoking history (current or former smoker vs. never smoker), sex, race, ethnicity, and stage (I, II, or III) at diagnosis. We also used primary tumor SNV/indel information for 5 genes (*TP53*, *KRAS*, *EGFR*, *BRAF*, *PIK3CA*) and copy number alteration data for 5 genes (*EGFR*, *PIK3CA*, *MET*, *KRAS*, *FGFR1*). Among mutations, only nonsynonymous point mutations, frameshift mutations, and splice site mutations were considered.

Multivariate Cox proportional hazards models for the time to first distant metastasis and for the time to bone, brain, and liver metastases were fit using the `coxph` function in the R survival package, version 3.2¹⁸, with right censoring at the date of death or last patient contact, such that the competing risk of death was addressed by analyzing the cause-specific hazard of distant metastasis. Wald test *p*-values for each covariate were pooled across all mutations/CNAs tested for each metastasis site and adjusted for multiple hypotheses^{19,20} using the Benjamini-Hochberg method, and covariates with adjusted *p*-value < 0.05 were considered significant. Confidence intervals for the hazard ratios were adjusted for multiple comparisons using the Bonferroni method.

Statistical analysis of the effect of TP53 mutations on patient survival after NSCLC diagnosis. After observing that mutations in *TP53* were associated with increased risk of distant metastasis, multivariable Cox proportional hazards modeling was used to measure whether associations between primary tumor *TP53* mutation status were related to overall survival after diagnosis of stage I-III NSCLC. This model incorporated the demographic, clinical, and genomic covariates used in the time-to-metastasis models (age, sex, race, ethnicity, smoking history, stage at diagnosis, and 10 total mutation/copy number alteration variables). Risk set adjustment²¹ was not performed, since informative cohort entry has previously been demonstrated in clinico-genomic datasets^{12,13}, and risk set adjustment could still yield biased results in the event of informative entry. Since this analysis was designed to specifically assess the effect of *TP53* mutations on patient survival, no correction for multiple hypotheses was performed.

Data availability

Genomic and clinical data for the AACR Project GENIE BPC NSCLC cohort is publicly available at <http://www.synapse.org/bpc>.

Received: 11 March 2022; Accepted: 27 September 2022

Published online: 09 November 2022

References

1. SEER Cancer statistics review, 1975–2016.
2. Chen, V. W. *et al.* Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. *Cancer* **120**, 3781–3792 (2014).
3. Kelsey, C. R. *et al.* Local recurrence after surgery for early stage lung cancer. *Cancer* **115**, 5218–5227 (2009).
4. Galvez, C. *et al.* The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. *Oncotarget* **11**, 1953–1960 (2020).
5. Mak, R. H. *et al.* Outcomes by EGFR, KRAS, and ALK genotype after combined modality therapy for locally advanced non-small-cell lung cancer. *JCO Precis. Oncol.* **2**, 1–18. <https://doi.org/10.1200/PO.17.00219> (2018).
6. AACR Project GENIE Consortium. AACR project GENIE: Powering precision medicine through an international consortium. *Cancer Discov.* **7**, 818–831 (2017).
7. Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A. & Chan, C. S. Why are there hotspot mutations in the TP53 gene in human cancers?. *Cell Death Differ.* **25**, 154–160 (2018).
8. Bouaoun, L. *et al.* TP53 variations in human cancers: New lessons from the IARC TP53 database and genomics data. *Hum. Mutat.* **37**, 865–876 (2016).
9. Alexandrov, L. B. *et al.* Mutational signatures associated with tobacco smoking in human cancer. *Science* **354**, 618–622 (2016).
10. Giacomelli, A. O. *et al.* Mutational processes shape the landscape of TP53 mutations in human cancer. *Nat. Genet.* **50**, 1381–1387 (2018).
11. Kong, L. R. *et al.* Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. *Nat. Commun.* **11**, 2086 (2020).
12. Kehl, K. L., Schrag, D., Hassett, M. J. & Uno, H. Assessment of temporal selection bias in genomic testing in a cohort of patients with cancer. *JAMA Netw. Open* **3**, e206976 (2020).
13. Backenroth, D. *et al.* Accounting for delayed entry in analyses of overall survival in clinico-genomic databases. *Cancer Epidemiol. Biomark. Prev.* **31**, 1195–1201 (2022).
14. Ma, X. *et al.* Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. *Mol. Oncol.* **8**, 555–564 (2014).

15. Tsao, M.-S. *et al.* Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. *JCO* **25**, 5240–5247 (2007).
16. Wakelee, H. A. *et al.* IMPower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB–IIIA non-small cell lung cancer (NSCLC). *JCO* **39**, 8500–8500 (2021).
17. Schrag, D. Real-World Applications of GENIE and a Taxonomy for Defining Cancer Outcomes. (2018).
18. Therneau, T. M. *A Package for Survival Analysis in R*. (2021).
19. Vickerstaff, V., Omar, R. Z. & Ambler, G. Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes. *BMC Med. Res. Methodol.* **19**, 129 (2019).
20. European Medicines Agency. Guideline on multiplicity issues in clinical trials. (2016).
21. Brown, S. *et al.* Implications of selection bias due to delayed study entry in clinical genomic studies. *JAMA Oncol.* **8**, 287–291 (2022).

Acknowledgements

We thank members of the Michor Lab for discussion and comments. The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry as well as members of the AACR Project GENIE consortium for their commitment to data sharing (full list of consortium members given in the Supplementary Information). Interpretations are the responsibility of study authors.

Author contributions

D.V.E., K.K., and F.M. designed the study. D.V.E. and K.K. performed all analyses and wrote the initial draft of the paper. Clinical data collection and curation was done by the AACR Project GENIE Consortium, led by D.S., E.L., J. L.W., G.R., M.L.-N., and P.L.B. F.M. supervised the study, with assistance from K.L.K. and biostatistics guidance from P.C. All authors reviewed and edited the final manuscript.

Funding

National Cancer Institute, USA

Competing interests

K.L.K. reports serving as a consultant/advisor to Aetion, receiving funding from the American Association for Cancer Research related to this work, and receiving honoraria from Roche and IBM. J. L.W. reports receiving funding from the American Association for Cancer Research related to this work, and receiving funding from the National Institutes of Health, consulting fees from Westat, Roche, Melax Tech, Flatiron Health, and ownership of HemOnc.org LLC, outside the submitted work. D.V.E. is a shareholder of Fractal Therapeutics. F.M. is a co-founder of and has equity in Harbinger Health, has equity in Zephyr AI, and serves as a consultant for Harbinger Health, Zephyr AI, and Red Cell Partners. F.M. declares that none of these relationships are directly or indirectly related to the content of this manuscript. All other authors do not have any conflicts.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-21448-1>.

Correspondence and requests for materials should be addressed to F.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

for the AACR Project GENIE Consortium represented by Shawn Sweeney

Michael Fiandalo¹⁷, Margaret Foti¹⁷, Yekaterina Khotskaya¹⁷, Jocelyn Lee¹⁷, Nicole Peters¹⁷, Shawn Sweeney¹⁷, Jean Abraham¹⁸, James D. Brenton¹⁸, Carlos Caldas¹⁸, Gary Doherty¹⁸, Birgit Nimmervoll¹⁸, Karen Pinilla¹⁸, Jose-Ezequiel Martin¹⁸, Oscar M. Rueda¹⁸, Stephen-John Sammut¹⁸, Dilrini Silva¹⁸, Kajia Cao¹⁹, Allison P. Heath¹⁹, Marilyn Li¹⁹, Jena Lilly¹⁹, Suzanne MacFarland¹⁹, John M. Maris¹⁹, Jennifer L. Mason¹⁹, Allison M. Morgan¹⁹, Adam Resnick¹⁹, Mark Welsh¹⁹, Yuankun Zhu¹⁹, Bruce Johnson¹, Yvonne Li¹, Lynette Sholl¹, Ron Beaudoin¹, Roshni Biswas¹, Ethan Cerami¹, Oya Cushing¹, Deepa Dand¹, Matthew Ducar¹, Alexander

Gusev¹, William C. Hahn¹, Kevin Haigis¹, Michael Hassett¹, Katherine A. Janeway¹, Pasi Jänne¹, Arundhati Jawale¹, Jason Johnson¹, Kenneth L. Kehl¹, Priti Kumari¹, Valerie Laucks¹, Eva Lepisto¹, Neal Lindeman¹, James Lindsay¹, Amanda Lueders¹, Laura Macconail¹, Monica Manam¹, Tali Mazor¹, Diana Miller¹, Ashley Newcomb¹, John Orechia¹, Andrea Ovalle¹, Asha Postle¹, Daniel Quinn¹, Brendan Reardon¹, Barrett Rollins¹, Priyanka Shivdasani¹, Angela Tramontano¹, Eliezer Van Allen¹, Stephen C. Van Nostrand¹, Jonathan Bell²⁰, Michael B. Datto²⁰, Michelle Green²⁰, Chris Hubbard²⁰, Shannon J. McCall²⁰, Niharika B. Mettu²⁰, John H. Strickler²⁰, Fabrice Andre²¹, Benjamin Besse²¹, Marc Deloger²¹, Semih Dogan²¹, Antoine Italiano²¹, Yohann Lorient²¹, Lacroix Ludovic²¹, Stefan Michels²¹, Jean Scoazec²¹, Alicia Tran-Dien²¹, Gilles Vassal²¹, Christopher E. Freeman²², Susan J. Hsiao²², Matthew Ingham²², Jiahong Pang²², Raul Rabadan²², Lira Camille Roman²², Richard Carvajal²², Raymond DuBois²³, Maria E. Arcila⁷, Ryma Benayed⁷, Michael F. Berger⁷, Marufur Bhuiya⁷, A. Rose Brannon⁷, Samantha Brown⁷, Debyani Chakravarty⁷, Cynthia Chu⁷, Ino de Bruijn⁷, Jesse Galle⁷, Jianjiong Gao⁷, Stu Gardos⁷, Benjamin Gross⁷, Ritika Kundra⁷, Andrew L. Kung⁷, Marc Ladanyi⁷, Jessica A. Lavery⁷, Xiang Li⁷, Aaron Lisman⁷, Brooke Mastrogiacomo⁷, Caroline McCarthy⁷, Chelsea Nichols⁷, Angelica Ochoa⁷, Katherine S. Panageas⁷, John Philip⁷, Shirin Pillai⁷, Gregory J. Riely⁷, Hira Rizvi⁷, Julia Rudolph⁷, Charles L. Sawyers⁷, Deborah Schrag⁷, Nikolaus Schultz⁷, Julian Schwartz⁷, Robert Sheridan⁷, David Solit⁷, Avery Wang⁷, Manda Wilson⁷, Ahmet Zehir⁷, Hongxin Zhang⁷, Gaofei Zhao⁷, Lailah Ahmed²⁴, Philippe L. Bedard²⁴, Jeffrey P. Bruce²⁴, Helen Chow²⁴, Sophie Cooke²⁴, Samantha Del Rossi²⁴, Sam Felicen²⁴, Sevan Hakgor²⁴, Prasanna Jagannathan²⁴, Suzanne Kamel-Reid²⁴, Geeta Krishna²⁴, Natasha Leigh²⁴, Zhibin Lu²⁴, Alisha Nguyen²⁴, Leslie Oldfield²⁴, Demi Plagianakos²⁴, Trevor J. Pugh²⁴, Alisha Rizvi²⁴, Peter Sabatini²⁴, Elizabeth Shah²⁴, Nitthusha Singaravelan²⁴, Lillian Siu²⁴, Gunjan Srivastava²⁴, Natalie Stickle²⁴, Tracy Stockley²⁴, Marian Tang²⁴, Carlos Virtanen²⁴, Stuart Watt²⁴, Celeste Yu²⁴, Brady Bernard²⁵, Carlo Bifulco²⁵, Julie L. Cramer²⁵, Soohee Lee²⁵, Brian Piening²⁵, Sheila Reynolds²⁵, Joseph Slagel²⁵, Paul Tittel²⁵, Walter Urba²⁵, Jake VanCampen²⁵, Roshanthi Weerasinghe²⁵, Alyssa Acebedo²⁶, Justin Guinney²⁶, Xindi Guo²⁶, Haley Hunter-Zinck²⁶, Thomas Yu²⁶, Kristen Dang²⁶, Valsamo Anagnostou²⁷, Alexander Baras²⁷, Julie Brahmer²⁷, Christopher Gocke²⁷, Robert B. Scharpf²⁷, Jessica Tao²⁷, Victor E. Velculescu²⁷, Shlece Alexander²⁸, Neil Bailey²⁸, Philip Gold²⁸, Mariska Bierkens²⁹, Jan de Graaf²⁹, Jan Hudeček²⁹, Gerrit A. Meijer²⁹, Kim Monkhorst²⁹, Kris G. Samsom²⁹, Joyce Sanders²⁹, Gabe Sonke²⁹, Jelle ten Hoeve²⁹, Tony van de Velde²⁹, José van den Berg²⁹, Emile Voest²⁹, George Steinhardt³⁰, Sabah Kadri³⁰, Wanjari Pankhuri³⁰, Peng Wang³⁰, Jeremy Segal³⁰, Christine Mounq³¹, Carlos Espinosa-Mendez³¹, Henry J. Martell³¹, Courtney Onodera³¹, Ana Quintanar Alfaro³¹, E. Alejandro Sweet-Cordero³¹, Eric Talevich³¹, Michelle Turski³¹, Laura Van't Veer³¹, Amanda Wren³¹, Susana Aguilar³², Rodrigo Dienstmann³², Francesco Mancuso³², Paolo Nuciforo³², Josep Taberner³², Cristina Viaplana³², Ana Vivancos³², Ingrid Anderson³³, Sandip Chaugai³³, Joseph Coco³³, Daniel Fabbri³³, Doug Johnson³³, Leigh Jones³³, Xuanyi Li³³, Christine Lovly³³, Sanjay Mishra³³, Kathleen Mittendorf³³, Li Wen³³, Yuanchu James Yang³³, Chen Ye³³, Marilyn Holt³³, Michele L. LeNoue-Newton³³, Christine M. Micheel³³, Ben H. Park³³, Samuel M. Rubinstein³³, Thomas Stricker³³, Lucy Wang³³, Jeremy Warner³³, Meijian Guan³⁴, Guangxu Jin³⁴, Liang Liu³⁴, Umit Topaloglu³⁴, Cetin Urtis³⁴, Wei Zhang³⁴, Michael D'Eletto³⁵, Stephen Hutchison³⁵, Janina Longtine³⁵ & Zenta Walther³⁵

¹⁷American Association for Cancer Research, Philadelphia, PA, USA. ¹⁸Cancer Research UK Cambridge Centre, Cambridge, UK. ¹⁹Children's Hospital of Philadelphia, Philadelphia, PA, USA. ²⁰Duke University (Duke Cancer Institute), Durham, NC, USA. ²¹Gustave Roussy Cancer Campus, Paris-Villejuif, France. ²²Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. ²³Medical University of South Carolina, Charleston, SC, USA. ²⁴Princess Margaret Cancer Centre, Toronto, ON, Canada. ²⁵Providence Cancer Institute, Portland, OR, USA. ²⁶Sage Bionetworks, Seattle, WA, USA. ²⁷Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ²⁸Swedish Cancer Institute, Seattle, WA, USA. ²⁹The Netherlands Cancer Institute, Amsterdam, Utrecht, The Netherlands. ³⁰The University of Chicago Comprehensive Cancer Center, Chicago, IL, USA. ³¹Diller Family Comprehensive Cancer Center, University of California-San Francisco (UCSF) Helen, San Francisco, CA, USA. ³²Vall d' Hebron Institute of Oncology, Barcelona, Spain. ³³Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. ³⁴Wake Forest University Health Sciences (Wake Forest Baptist Medical Center), Winston-Salem, NC, USA. ³⁵Yale University (Yale Cancer Center), New Haven, CT, USA.